Firebrick Pharma Shares Surge After Launching Nasal Spray In The US

Firebrick Pharma Ltd (ASX: FRE) shares were trading 39% higher intra-day at A$0.071 after launching the Nasodine nasal spray in the United States.

Nasodine is now available to purchase from Firebrick’s US website ( and online promotion is starting this week.

Nasal hygiene product

In the US market, Nasodine will be marketed for “nasal hygiene” purposes, avoiding any claims of therapeutic benefits.

Legal advice obtained by Firebrick allows them to market the product without prior approval from the FDA.

This strategy aligns with several other PVP-I (iodopovidone) nasal sprays already established in the US market.

Transition to commercial pharmaceutical business

Firebrick Executive Chairman Dr Peter Molloy said: “Launching Nasodine into the world’s premier pharmaceutical market is a momentous event for our company, culminating more than 10 years of R&D and heralding our transition to a commercial pharmaceutical business.”

Dr. Molloy further highlighted that Nasodine will be the only PVP-I nasal spray in the US with demonstrated safety through clinical trials.

US-based manufacturing

In the US, Nasodine is manufactured for Firebrick by a contract manufacturer who recently completed its first US commercial batch of finished product.

Firebrick has also partnered with a US-based online marketing agency to develop and execute a social media advertising campaign.

Initially, Nasodine will be marketed online only, although in the future it is expected to be available in US pharmacies as well.

Firebrick has additional products in development and anticipates introducing some of them to the US market.




JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest